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Abstract: Staphylococcus aureus bloodstream infection (SA-BSI) is an infection with increasing
morbidity and mortality. Concomitant Staphylococcus aureus bacteriuria (SABU) frequently occurs
in patients with SA-BSI. It is considered as either a sign of exacerbation of SA-BSI or a primary
source in terms of urosepsis. The clinical implications are still under investigation. In this study,
we investigated the role of SABU in patients with SA-BSI and its effect on the patients’ mortality.
We performed a retrospective cohort study that included all patients in our university hospital
(Charité Universitätsmedizin Berlin) between 1 January 2014 and 31 March 2017. We included all
patients with positive blood cultures for Staphylococcus aureus who had a urine culture 48 h before
or after the first positive blood culture. We identified cases while using the microbiology database
and collected additional demographic and clinical parameters, retrospectively, from patient files and
charts. We conducted univariate analyses and multivariable Cox regression analysis to evaluate the
risk factors for in-hospital mortality. 202 patients met the eligibility criteria. Overall, 55 patients
(27.5%) died during their hospital stay. Cox regression showed SABU (OR 2.3), Pitt Bacteremia
Score (OR 1.2), as well as moderate to severe liver disease (OR 2.1) to be independent risk factors
for in-hospital mortality. Our data indicates that SABU in patients with concurrent SA-BSI is a
prognostic marker for in-hospital death. Further studies are needed for evaluating implications for
therapeutic optimization.
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1. Introduction
Staphylococcus aureus bacteremia (SA-BSI) is a severe and frequent bacterial infection [1].
The mortality of patients remains elevated despite effective diagnostic and therapeutic options,
even in highly developed healthcare settings [2]. Several official guideline and recommendations on
management of SA-BSI are available [2–4]. The German Society of Infectious Diseases has published
recommendations on the diagnosis and treatment of SA-BSI to improve the care and outcomes of
patients [3]. Since the late 1970′s, several reports have been published regarding the clinical significance
of Staphylococcus aureus bacteriuria (SABU) in patients with SA-BSI [5]. The role of SABU described in
the literature covers a wide range of potential implications for patients from asymptomatic colonization
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to primary catheter associated urinary tract infection to hematogenous seeding in patients with
SA-BSI [6,7]. While certain toxins were shown to play a role in severity of SA-BSI [8], the invasion
of host cells and virulence of S. aureus is largely determined by fibronectin binding and it could
explain intrarenal translocation into the urinary tract [9]. A recent in-vivo study suggested that
urinary tract colonization and infection with MRSA is based on the release of fibrinogen after catheter
associated tissue damage in mice and humans [10]. In relation to that, SABU was described as a
prognostic factor in the identification of complicated SA-BSI [11], as well as being associated with
increased mortality in patients with SA-BSI [12,13]. A recent report found that only few patients with a
SABU had a concomitant SA-BSI (6.9%) [7]. Moreover, a national study from Iceland showed that,
after excluding primary SABU, 10.5% of patients with SA-BSI still developed secondary SABU [14].
Nevertheless, the clinical interpretation of this situation remains controversial [15]. Therefore, our
objective was to describe the potential role of SABU in patients with SA-BSI and evaluate its influence
on in-hospital mortality.
2. Experimental Section
2.1. Setting, Study Design and Data Collection
The study was conducted at three different tertiary care hospitals of Charité Universitätsmedizin
Berlin, with 3011 beds in total. Prior to the study, we obtained an official ethics-vote from the Charité
Universitätsmedizin ethics committee (internal processing key EA2/130/19). The investigation was
performed as a retrospective cohort study that aimed to include all cases of SA-BSI in patients 18 years
of age or older, between 1 January 2014 and 31 March 2017. Cases were identified in the Charité
microbiology database as patients with blood cultures positive for Staphylococcus aureus who had had
urine that was sampled within 48 h prior or after first S. aureus-positive blood culture. For all of the
patients enrolled in this study, the following demographic and clinical characteristics were collected:
age, sex, in-hospital death, length of hospital stay (LOS), day of BSI onset, and stay on an intensive
care unit (days). Length of stay in total and after BSI onset were defined as length of stay until death or
discharge. We assessed the PITT Bacteremia Score on the day of BSI onset retrospectively from patient
files in order to evaluate the severity of the bloodstream infection [16]. The Charlson comorbidity
index (CCI) was obtained on the basis of the patients’ diagnosed comorbidities while using the method
of Charlson et al. [17] and the adaptation for the ICD-10 by Thygesen et al. [18].
2.2. Definitions
Cases were defined as patients with SA-BSI during the study period. The onset of SA-BSI was
defined as the date of the sampling of the first blood culture with growth of Staphylococcus aureus.
SA-BSI was considered to be hospital-onset if it occurred after the second day of hospitalization
(>48 h after admission). SABU was defined as a detection of Staphylococcus aureus in a urine sample.
Urinary Catheter prior to onset was defined as an indwelling urinary catheter for any length of
time within seven days prior to onset of SA-BSI. Effective antimicrobial treatment was defined as
flucloxacillin or cefazolin i.v. treatment in MSSA and vancomycin, linezolid, daptomycin, or ceftaroline
treatment in MRSA after lab results were available (72 h) [19,20]. Mortality was assessed based on
discharge alive or in-hospital death.
2.3. Statistical Methods
Descriptive univariate analyses were performed for the total cohort, being stratified by in-hospital
death and by SABU. The median and the interquartile range (IQR) were calculated for continuous
parameters; the number and percentage were calculated for binary parameters. Univariate differences
were tested while using the Wilcoxon rank-sum test for continuous variables and the Chi-square test
for binary variables. All tests of significance were two-tailed with a p-value of <0.05 considered to be
significant. Univariate survival analysis was performed as a Kaplan–Meier curve stratified by SABU.
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We performed a Cox-proportional hazard regression adjusting for LOS after BSI in order to analyze
potential factors on in-hospital mortality in a multivariable analysis. The variables included in the
analysis were the ones with a p-value < 0.100 in the univariate analysis and potential influence on the
endpoint: SABU, Pitt-Score, ICU admission after onset of SA-BSI, urinary catheter prior to sampling,
peptic ulcer, diabetes with and without complication, renal disease, and moderate to severe liver disease.
As the duration of antimicrobial therapy depended on the LOS after BSI onset, it was not included.
We calculated adjusted hazard ratios (HR) with a 95% confidence interval for in-hospital death after
onset of SA-BSI while using a stepwise forward approach. For the final model, variables with p-values
of ≤0.05 were included and variables with p > 0.05 were excluded while using a stepwise forward
approach. All of the analyses were performed while using SPSS (IBM SPSS statistics, Somer, NY, USA)
and SAS (SAS Institute, Cary, NC, USA).
2.4. Microbiological Methods
Urine sampling was performed with native mid-stream or catheter urine in a standard 10mL sterile
Urin-Monovette® (Sarstedt, Nümbrecht, Germany). The samples were cultured for up to forty-eight
hours. If a blood stream infection was suspected, the blood cultures were drawn and incubated for up
to seven days while using standard blood culture bottles (BACTEC®, Becton Dickinson, Heidelberg,
Germany). Gram staining and subculturing were performed if growth was detected. MALDI TOF
MS® and Vitek 2® automated system (Biomerieux, Marcy l’etoile, France) were used for identification
and susceptibility testing of bacterial strains. They were interpreted while using EUCAST definitions.
3. Results
In the study period, 1139 patients were diagnosed with S. aureus bacteremia. In addition,
206 patients also had at least one urine culture examination within 48 h before or after SA-BSI. Of these
patients, we had complete datasets of 202 patients (Figure 1). The remaining patients had to be removed
due to incomplete data.
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Figure 1. Flowchart depicting patient recruitment based on blood culture isolates and urine testing.
In this cohort (Table 1), the overall in-hospital mortality after onset of SA-BSI was 27.23% (n = 55).
Univariate analysis showed that patients that died during their treatment in hospital had a median
PITT bacteremia score of two (IQR, 1–8). In comparison, patients that were discharged from hospital
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had a significantly lower score of one (IQR, 0–2). Patients that died during their hospital stay were
more likely to have been admitted to an ICU after the onset of SA-BSI when compared to surviving
patients. They also had shorter LOS overall and stayed for shorter periods after the onset of SA-BSI
(Table 2). Their antimicrobial treatment was shorter and they were less likely to receive antimicrobial
treatment for >14 days (Table 2 and Table S1). However, they were more likely to have a urinary
catheter prior to onset of SA-BSI and were more likely to have urine cultures that were positive for
S. aureus (Table 2).
Table 1. Demographic data on the study cohort.
Total N = 202
Median (IQR)/% (n)
Age in years 71 (59–80)
Male gender 60% (121)
in-hospital death 27% (55)
Onset of SA-BSI after admission in days 2 (1–10)
LOS in days 22 (12–42)
ICU admission after onset of SA-BSI 61% (124)
SABU 39% (78)
SA-BSI with MRSA 25% (50)
Pitt-Score 1 (0–4)
Charlson comorbidity index 7 (5–10)
Effective antimicrobial treatment 42% (86)
Spondylodiszitis 2% (4)
Endocarditis 8% (17)
Cardiac device 6% (13)
Artificial heart valve 6% (13)
Dialysis prior to sampling 15% (30)
Port catheter prior to sampling 9% (19)
CVC prior to sampling 31% (63)
Urinary catheter prior to sampling 49% (98)
Continuous variables are presented as median and interquartile range (IQR). Categorical variables are presented as
number (%). BSI: bloodstream infection, ICU: intensive care unit, LOS: length of stay, and SABU: S. aureus bacteriuria.






N = 55 p-Value
Median (IQR)/% (n) Median (IQR)/% (n) Median (IQR)/% (n)
LOS in days 22 (12–42) 28 (15–47) 13 (5–28) <0.001
LOS after SA-BSI onset in days 16 (8–30) 18 (11–37) 8 (2–19) <0.001
Pitt-Score 1 (0–4) 1 (0–2) 2 (1–8) <0.001
SABU 39% (78) 33% (49) 53% (29) 0.012
Peptic ulcer 4% (9) 6% (9) − 0.060
Diabetes without complication 28% (56) 32% (47) 16% (9) 0.027
Diabetes with complication 9% (19) 12% (17) 4% (2) 0.086
Renal disease 62% (126) 59% (86) 73% (40) 0.063
Moderate to severe liver disease 13% (27) 10% (14) 24% (13) 0.009
ICU admission after onset of SA-BSI 61% (124) 55% (81) 78% (43) 0.003
Urinary catheter prior to sampling 49% (98) 44% (65) 60% (33) 0.058
Only the relevant results with a p-value ≤0.100 are shown, as they were further analyzed in the multivariable
analysis. A table of the entire univariate analysis can be found in the supplement under S1. Continuous variables
are presented as median and interquartile range (IQR). Categorical variables are presented as number (%). BSI:
bloodstream infection, LOS: length of stay, CCI: Charlson comorbidity index. ABX: antimicrobial therapy. SABU:
S. aureus bacteriuria.
We stratified the cohort into groups with an S. aureus-negative (SA-negative) or an S. aureus-positive
(SA-positive) urine culture (Table 3 and Table S2). Univariate analysis in this comparison revealed that
patients with SA-positive urine had a higher mean CCI and higher in-hospital mortality than patients
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with SA-negative urine. The mean onset of SA-BSI was earlier (day 1; IQR 0–7) than in patients with
SA-negative urine (day 4; IQR 1–11). Patients with SA-positive urine had a shorter LOS overall and
shorter LOS after the onset of SA-BSI.
Univariate survival curve (Kaplan–Meier) showed a higher risk of death in patients with SA-BSI
and concurrent SABU than those with SA-BSI only (Figure 2).
Table 3. Univariate analysis of the study cohort stratified by urine positive or negative for
Staphylococcus aureus.
Negative Urine Positive Urine/SABU
p-Value
Median (IQR)/% (n) Median (IQR)/% (n)
Total 100% (124) 100% (78) not applicable
Male gender 52% (65) 72% (56) 0.008
Onset of SA-BSI after admission in days 4 (1–11) 1 (0–7) 0.044
LOS in days 27 (15–45) 18 (7–39) 0.004
LOS after SA-BSI onset in days 18 (10–32) 14 (5–28) 0.018
Pitt-Score 11 (9–15) 10 (5–14) 0.062
Charlson comorbidity index 7 (5–9) 8 (6–10) 0.008
In-hospital mortality (0 = no;1 = yes) 21% (26) 37% (29) 0.012
Cardiac insufficiency 38% (47) 26% (20) 0.072
Connective tissue disease 4% (5) − 0.073
Malign tumor 13% (16) 31% (24) 0.002
Metastatic solid tumor 13% (16) 24% (19) 0.036
Hemiplegia 7% (8) 15% (12) 0.038
Lymphoma 10% (12) 3% (2) 0.053
Shown are only the results with a p-value ≤ 0.100. A table of the entire univariate analysis can be found in the
supplement under S2. Continuous variables presented as median and interquartile range (IQR). Categorical variables
are presented as number (%). BSI: bloodstream infection. LOS: length of stay, CCI: Charlson comorbidity index.
ABX: antimicrobial therapy.J. Clin. Med. 2020, 9, x FOR PEER REVIEW 6 of 10 
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In a Cox regression analysis, we took the length of hospital stay into consideration. In this analysis,
a Pitt Bacteremia Score of >1, SA-positive urine culture, as well as moderate to severe liver disease,
were independent risk factors (Table 4 and Figure 3).
Table 4. The results of cox regression for in-hospital death after S. aureus bloodstream infection.
p-Value Odds Ratio CI95 Low CI95 High
SABU 0.003 2.281 1.224 3.899
Pitt bacteraemia score <0.001 1.195 1.107 1.289
Moderate to severe liver disease 0.023 2.062 1.104 3.853
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4. Discussion
We identified SABU as an independent and clinically relevant risk factor for in-hospital
mortality in patients with SA-BSI. This finding is consistent with earlier reports [12,13]. However,
the pathophysiological reason for SABU can vary and it is often not associated with SA-BSI [21].
SABU is considered to be a secondary seeding to SA-BSI [21]. Others question this theory and
maintain that SABU mainly occurs because of the urinary catheter-associated contamination or primary
infection [15]. A recent population-based study from Canada showed that only 7% of all patients
with a SABU also develop a SA-BSI [7]. While there were urine samples that were derived from
catheterized patients in our cohort, the rate of catheterization prior to BSI onset was similar for patients
with and without SABU. Hence, contamination as an underlying reason seems to be less likely. This is
supported by the results of earlier studies. Lafon et al. identified community-acquired SABU to be
associated with left sided endocarditis in patients without risk for urinary tract colonization [22].
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A recent Meta-analysis described SABU as an important predictor for SA-BSI and endocarditis in
patients without urinary tract-infection or colonization [21]. In addition, nosocomial BSI were observed
in higher frequencies among patients without SABU. This finding is potentially explained by the
observation that nosocomial SA-BSI are often based on primary BSIs, which are frequently associated
with vascular catheters [23]. Vascular catheter association are common in nosocomial SA-BSI and they
have a lower mortality when compared to community acquired SA-BSI [24]. However, we conducted a
multivariable analysis to evaluate the risk factors for SABU (Supplement Table S3). The results showed
that the development of SABU in our cohort was independent from the timing of BSI onset.
Our multivariable logistic regression identified moderate to severe liver disease to be an
independent risk factor for in-hospital mortality after S. aureus bloodstream infection, which was
previously known [22,25]. Moreover, Bassetti et al. described liver disease as a risk factor, especially in
patients with community-acquired SA-BSI [26].
The Pitt Bacteremia Score showed an independent direct correlation with hospital mortality
in patients with SA-BSI. This finding is in line with other studies [27,28]. Roth et al. found the
Pitt Bacteremia Score to have a low positive predictive value, especially in short-term mortality for
SA-BSI [29]. However, as this might be true in low mortality risk populations (their median Pitt
Bacteremia Score was 0 and median CCI was 3), cohorts with an overall higher mortality risk yield a
higher positive predictive value (PPV). The median Pitt Bacteremia Score in our cohort was 1, and the
median CCI was 7, indicating a cohort with a high mortality risk.
In-hospital mortality of patients with SA-BSI was 27%. Similar in-hospital mortality rates have
been described for patients with SA-BSI in comparable settings [30]. Hence, we assume that our
study has certain representativeness. However, there are limitations to our study that have to be
acknowledged: (i) This is a retrospective cohort study from a single university hospital center. Therefore,
the selection of our cohort is influenced by the microbiological sampling strategies, especially in regards
to urine samples. Our institutional guidelines give clear recommendations on sampling strategies
to reduce contamination. It is likely that urine was sampled either when patients had symptoms
suggestive of urinary tract infections or when patients were admitted with symptoms of a systemic
infection that did not have a clear-cut focus. This certainly applies to patients that are admitted to a
hospital because of a systemic infection. Additionally, we neither analyzed patients with SABU for
whom we did not have blood culture samples, nor patients with SA-BSI with end stage renal disease
that had anuria. (ii) We were unable to differentiate between the primary focus and secondary site in
patients with positive urine, since we did not record specific clinical symptoms for UTI. However, this is
not relevant to our objectives, since we focused on outcome parameters. (iii) S. aureus isolates were
neither tested for relation nor virulence factors in order to account for differences. (iv) Only a small
portion of patients received a treatment strategy the followed national and international guidelines.
While it is necessary to validate our results after improvement in the management of patients with
SA-BSI, the choices of substances and the duration of antimicrobial treatment were independent of
urine sample results.
5. Conclusions
Our study demonstrates that SABU is a relevant prognostic marker for in-hospital mortality in
patients with SA-BSI. This suggests a potential benefit from intensified treatment strategies, as well as
from efforts to identify the primary source of SA-BSI. Further clinical studies are needed to confirm
this finding.
Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/9/2/508/s1,
Table S1: Univariate analysis of the whole cohort stratified by in-hospital death, Table S2: Univariate analysis
of the whole cohort stratified by urine positive or negative for Staphylococcus aureus, Table S3: Multivariable
logistic regression for risk factors on SABU.
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